LUPRON DEPOT Drug Patent Profile
✉ Email this page to a colleague
When do Lupron Depot patents expire, and when can generic versions of Lupron Depot launch?
Lupron Depot is a drug marketed by Abbvie Endocrine Inc and is included in five NDAs. There are two patents protecting this drug.
This drug has thirty-five patent family members in twenty-eight countries.
The generic ingredient in LUPRON DEPOT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lupron Depot
A generic version of LUPRON DEPOT was approved as leuprolide acetate by SANDOZ on August 4th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUPRON DEPOT?
- What are the global sales for LUPRON DEPOT?
- What is Average Wholesale Price for LUPRON DEPOT?
Summary for LUPRON DEPOT
| International Patents: | 35 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 57 |
| Clinical Trials: | 134 |
| Drug Prices: | Drug price information for LUPRON DEPOT |
| What excipients (inactive ingredients) are in LUPRON DEPOT? | LUPRON DEPOT excipients list |
| DailyMed Link: | LUPRON DEPOT at DailyMed |
Recent Clinical Trials for LUPRON DEPOT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| NRG Oncology | Phase 2 |
| Prostate Cancer Foundation | Phase 2 |
| Panbela Therapeutics | Phase 2 |
US Patents and Regulatory Information for LUPRON DEPOT
LUPRON DEPOT is protected by two US patents.
Patents protecting LUPRON DEPOT
Sustained-release composition and method for producing the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PALLIATIVE TREATMENT OF PROSTATE CANCER
Sustained-release composition and method for producing the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADVANCED PROSTATIC CANCER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020011-001 | Oct 22, 1990 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | POWDER;INTRAMUSCULAR | 020263-009 | Apr 14, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020517-003 | Jun 17, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020708-001 | Mar 7, 1997 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | POWDER;INTRAMUSCULAR | 020263-005 | Jan 21, 1994 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020517-003 | Jun 17, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | POWDER;INTRAMUSCULAR | 020263-009 | Apr 14, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LUPRON DEPOT
International Patents for LUPRON DEPOT
See the table below for patents covering LUPRON DEPOT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2007335406 | Sustained-release composition and method for producing the same | ⤷ Sign Up |
| Japan | 3191004 | ⤷ Sign Up | |
| Greece | 860332 | METHOD FOR PRODUCING MICROCAPSULE | ⤷ Sign Up |
| Norway | 910555 | ⤷ Sign Up | |
| New Zealand | 577281 | SUSTAINED-RELEASE COMPOSITION AND METHOD FOR PRODUCING THE SAME | ⤷ Sign Up |
| Portugal | 1330293 | ⤷ Sign Up | |
| Greece | 80818 | METHOD FOR PRODUCING MICROCAPSULE | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
